Balken W J
Fortschr Med. 1976 Sep 23;94(27):1504-6.
The present paper reports on the experience obtained in patients during treatment of rheumatoid arthritis with Azathioprine. The duration of treatment was on the average 16.5 months (minimum 1 month, maximum 54 months). The arthritic pains could be alleviated or even stopped completely in 73% of the cases. In 53.6% of the cases the morning stiffness was influenced favourably. The analgetic dose could be reduced in 54% of patients, who additionally received analgetics. Rheumatic attacks appeared rarely and also were of shorter duration and less severe. Therefore it can be concluded that Azathioprine has decreased the progredience of the disease. The main side-effects were gastrointestinal upsets. In 2 cases therapy had to be discontinued due to leucopenia. The results show that Azathioprine seems to be valuable for the treatment of severe rheumatoid arthritis. The overall effect can be considered as successful, but long-term therapy is necessary.
本文报告了使用硫唑嘌呤治疗类风湿性关节炎患者的经验。治疗时间平均为16.5个月(最短1个月,最长54个月)。73%的病例中关节疼痛可得到缓解甚至完全停止。53.6%的病例晨僵情况得到改善。在额外服用镇痛药的患者中,54%的患者镇痛药剂量可减少。风湿发作很少出现,且持续时间短、程度轻。因此可以得出结论,硫唑嘌呤降低了疾病的进展速度。主要副作用是胃肠道不适。2例因白细胞减少而不得不停止治疗。结果表明,硫唑嘌呤似乎对治疗重度类风湿性关节炎有价值。总体效果可认为是成功的,但需要长期治疗。